A Phase 3 interventional study of Fingolimod and Placebo in Relapsing Multiple Sclerosis, sponsored by Novartis. Completed at 25 sites in 9 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2012-06-19.
Sponsored by Novartis · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing fingolimod in Multiple Sclerosis — 2 open to participants now, 4 under way, 3 of them phase 3. fingolimod · Multiple Sclerosis.
Among the 34 studies testing fingolimod in Multiple Sclerosis, this one is the 22nd largest by enrollment, is one of 4 that started in 2010, is one of 12 in phase 3, and was the 11th registered.
3,271 studies on the registry are indexed under Multiple Sclerosis; 663 are open to participants now.
Browse Multiple Sclerosis studies →2 of the 34 studies testing fingolimod in Multiple Sclerosis are open now, in 3 countries. Recruiting first, the newest first:
TG Therapeutics, Inc. · Sites in United States, Poland, Slovakia
Ages 10–17
Biogen
Ages 10–17
By country, each count listing its studies:
fingolimod: first FDA approval 2010 (GILENYA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 431 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 212 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 13 · Phase 4 17
First in 2003; this study’s year is marked. 4 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 138 is above the median of 50 across 2,205 interventional studies indexed under Multiple Sclerosis.
Median enrollment 167 across the 34 interventional studies. Of the 28 that completed or were terminated, 23 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 34 have an industry lead sponsor. The 6 most frequent:
Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
106 studies in Multiple Sclerosis by Novartis: 9 open now, 24 under way, 6 of them phase 3. Of 78 finished, 45 (58%) have results posted.
Among the 106 studies in Multiple Sclerosis by Novartis, this one is the 35th largest by enrollment of the 64 interventional ones that give a count, is one of 6 that started in 2010, is one of 23 in phase 3, and was the 15th registered.
Novartis’s Multiple Sclerosis studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 34 studies testing fingolimod in Multiple Sclerosis, from their registry updates:
Among Novartis’s 106 in Multiple Sclerosis:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the effect of treatment with fingolimod on the immune response following seasonal influenza vaccination and tetanus booster injection in patients with relapsing MS.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received Fingolimod 0.5 mg capsules orally once daily for 12 weeks. At Week 6 of study treatment participants received a seasonal influenza vaccination and a tetanus booster vaccination.
Drug: Fingolimod · Biological: Seasonal influenza vaccine · Biological: Tetanus toxoid vaccine
Participants received placebo tablets orally once daily for 12 weeks. At Week 6 of study treatment participants received a seasonal influenza vaccination and a tetanus booster vaccination.
Drug: Placebo · Biological: Seasonal influenza vaccine · Biological: Tetanus toxoid vaccine
Fingolimod 0.5 mg capsules for oral administration.
Also known as: FTY720
Matching placebo capsules for oral administration.
Commercially available injectable influenza vaccine for the 2010/11 influenza season.
Also known as: Agrippal (TM)
Commercially available tetanus toxoid vaccine booster injection.
Also known as: Tetanol (TM)
Immune Response 3 Weeks After Seasonal Influenza Vaccination
Percentage of participants who responded to treatment with the seasonal influenza vaccine 3 weeks after vaccination. Response was defined as patients fulfilling one of the following criteria for at least one of the three strains contained in the seasonal influenza vaccine: * Seroconversion: The pre-vaccination antibody titer measurement was \<1:10 and the post-vaccination measurement is ≥1:40. * Significant increase in antibody titer: The pre-vaccination antibody titer measurement was ≥1:10 and the increase in antibody titer from this to the post-vaccination measurement is ≥ 4-fold.
Time frame: Week 6 (pre-vaccination) and 3 weeks after vaccination (Study week 9)
Immune Response 6 Weeks After Seasonal Influenza Vaccination
Percentage of participants who responded to treatment with the seasonal influenza vaccine 6 weeks after vaccination. Response was defined as patients fulfilling one of the following criteria for at least one of the three strains contained in the seasonal influenza vaccine: * Seroconversion: The pre-vaccination antibody titer measurement was \<1:10 and the post-vaccination measurement is ≥1:40. * Significant increase in antibody titer: The pre-vaccination antibody titer measurement was ≥1:10 and the increase in antibody titer from this to the post-vaccination measurement is ≥ 4-fold.
Time frame: Week 6 (pre-vaccination) and 6 weeks after vaccination (Study week 12).
Immune Response 3 Weeks After Tetanus Toxoid Booster
Percentage of participants with an immune response to a single dose of tetanus toxoid three weeks after vaccination. A patient was considered a responder to tetanus toxoid booster vaccination if one of the following criteria was met: 1. Seroconversion: The pre-vaccination antibody titer measurement was \<0.1 IU/ml and the post-vaccination measurement was ≥0.4 IU/ml. 2. Significant increase: The pre-vaccination antibody titer measurement was ≥0.1 IU/ml and the increase in antibody titer from this to the post-vaccination measurement was ≥4- fold.
Time frame: Week 6 (pre-vaccination) and 3 weeks after vaccination (Study Week 9)
Immune Response 6 Weeks After Tetanus Toxoid Booster
Percentage of participants with an immune response to a single dose of tetanus toxoid six weeks after vaccination. A patient was considered a responder to tetanus toxoid booster vaccination if one of the following criteria was met: 1. Seroconversion: The pre-vaccination antibody titer measurement was \<0.1 IU/ml and the post-vaccination measurement was ≥0.4 IU/ml. 2. Significant increase: The pre-vaccination antibody titer measurement was ≥0.1 IU/ml and the increase in antibody titer from this to the post-vaccination measurement was ≥4- fold.
Time frame: Week 6 (pre-vaccination) and 6 weeks after vaccination (Study Week 12)
Change From Baseline in Seasonal Influenza Vaccine Antibody-titer 3 Weeks After Vaccination
Change from Baseline was expressed by the ratio of post-vaccination to pre-vaccination antibody titer for each of the three strains included in the seasonal influenza vaccine. Inhibition of an immune response to each strain included in the seasonal influenza vaccine was assessed by the relative difference of the geometric mean antibody titer ratio on fingolimod as compared to placebo three weeks after a single dose of seasonal influenza vaccine.
Time frame: Pre-vaccination (Week 6) and 3 weeks after vaccination (Study Week 9).
Change From Baseline in Seasonal Influenza Vaccine Antibody-titer 6 Weeks After Vaccination
Change from Baseline was expressed by the ratio of post-vaccination to pre-vaccination antibody titer for each of the three strains included in the seasonal influenza vaccine. Inhibition of an immune response to each strain included in the seasonal influenza vaccine was assessed by the relative difference of the geometric mean antibody titer ratio on fingolimod as compared to placebo six weeks after a single dose of seasonal influenza vaccine.
Time frame: Pre-vaccination (Week 6) and 6 weeks after vaccination (Study Week 12).
Number of Participants With Adverse Events (AEs)
Relationship to study drug was determined by the investigator (suspected/not suspected). A serious AE is defined as an event which fulfills one of the following criteria: * is fatal or life-threatening; * results in persistent or significant disability/incapacity; * constitutes a congenital anomaly/birth defect; * requires inpatient hospitalization or prolongation of existing hospitalization; * is medically significant, i.e., jeopardizes the patient or may require intervention to prevent one of the outcomes listed above.
Time frame: From first dose of study drug until 45 days after the last dose of study drug (130 days).
| Milestone | Fingolimod | Placebo |
|---|---|---|
| Started | 95 | 43 |
| Completed | 93 | 43 |
| Not completed | 2 | 0 |
| Withdrew: Administrative problems | 1 | 0 |
| Withdrew: Adverse event | 1 | 0 |
Percentage of participants who responded to treatment with the seasonal influenza vaccine 3 weeks after vaccination. Response was defined as patients fulfilling one of the following criteria for at least one of the three strains contained in the seasonal influenza vaccine: * Seroconversion: The pre-vaccination antibody titer measurement was \<1:10 and the post-vaccination measurement is ≥1:40. * Significant increase in antibody titer: The pre-vaccination antibody titer measurement was ≥1:10 and the increase in antibody titer from this to the post-vaccination measurement is ≥ 4-fold.
| percentage of participants | Fingolimod | Placebo |
|---|---|---|
| Immune Response 3 Weeks After Seasonal Influenza Vaccination | 53.3 | 83.7 |
Percentage of participants who responded to treatment with the seasonal influenza vaccine 6 weeks after vaccination. Response was defined as patients fulfilling one of the following criteria for at least one of the three strains contained in the seasonal influenza vaccine: * Seroconversion: The pre-vaccination antibody titer measurement was \<1:10 and the post-vaccination measurement is ≥1:40. * Significant increase in antibody titer: The pre-vaccination antibody titer measurement was ≥1:10 and the increase in antibody titer from this to the post-vaccination measurement is ≥ 4-fold.
| percentage of participants | Fingolimod | Placebo |
|---|---|---|
| Immune Response 6 Weeks After Seasonal Influenza Vaccination | 43.2 | 74.4 |
Percentage of participants with an immune response to a single dose of tetanus toxoid three weeks after vaccination. A patient was considered a responder to tetanus toxoid booster vaccination if one of the following criteria was met: 1. Seroconversion: The pre-vaccination antibody titer measurement was \<0.1 IU/ml and the post-vaccination measurement was ≥0.4 IU/ml. 2. Significant increase: The pre-vaccination antibody titer measurement was ≥0.1 IU/ml and the increase in antibody titer from this to the post-vaccination measurement was ≥4- fold.
| percentage of participants | Fingolimod | Placebo |
|---|---|---|
| Immune Response 3 Weeks After Tetanus Toxoid Booster | 40.0 | 60.5 |
Percentage of participants with an immune response to a single dose of tetanus toxoid six weeks after vaccination. A patient was considered a responder to tetanus toxoid booster vaccination if one of the following criteria was met: 1. Seroconversion: The pre-vaccination antibody titer measurement was \<0.1 IU/ml and the post-vaccination measurement was ≥0.4 IU/ml. 2. Significant increase: The pre-vaccination antibody titer measurement was ≥0.1 IU/ml and the increase in antibody titer from this to the post-vaccination measurement was ≥4- fold.
| percentage of participants | Fingolimod | Placebo |
|---|---|---|
| Immune Response 6 Weeks After Tetanus Toxoid Booster | 37.5 | 48.8 |
Change from Baseline was expressed by the ratio of post-vaccination to pre-vaccination antibody titer for each of the three strains included in the seasonal influenza vaccine. Inhibition of an immune response to each strain included in the seasonal influenza vaccine was assessed by the relative difference of the geometric mean antibody titer ratio on fingolimod as compared to placebo three weeks after a single dose of seasonal influenza vaccine.
| ratio | Fingolimod | Placebo |
|---|---|---|
| A/California/7/09(H1N1) | 2.45 | 4.14 |
| A/Perth/16/2009(H3N2) | 0.49 | 0.36 |
| B/Brisbane/60/2008 | 1.34 | 2.40 |
Change from Baseline was expressed by the ratio of post-vaccination to pre-vaccination antibody titer for each of the three strains included in the seasonal influenza vaccine. Inhibition of an immune response to each strain included in the seasonal influenza vaccine was assessed by the relative difference of the geometric mean antibody titer ratio on fingolimod as compared to placebo six weeks after a single dose of seasonal influenza vaccine.
| ratio | Fingolimod | Placebo |
|---|---|---|
| A/California/7/09(H1N1) | 1.81 | 2.91 |
| A/Perth/16/2009(H3N2) | 0.36 | 0.28 |
| B/Brisbane/60/2008 | 1.08 | 2.07 |
Relationship to study drug was determined by the investigator (suspected/not suspected). A serious AE is defined as an event which fulfills one of the following criteria: * is fatal or life-threatening; * results in persistent or significant disability/incapacity; * constitutes a congenital anomaly/birth defect; * requires inpatient hospitalization or prolongation of existing hospitalization; * is medically significant, i.e., jeopardizes the patient or may require intervention to prevent one of the outcomes listed above.
| participants | Fingolimod | Placebo |
|---|---|---|
| Any adverse event | 82 | 34 |
| AE related to study drug | 42 | 11 |
| Serious adverse event | 1 | 2 |
| Adverse events leading to discontinuation | 1 | 0 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Fingolimod | — | 1/95 (1.1%) | 51/95 (53.7%) |
| Placebo | — | 2/43 (4.7%) | 22/43 (51.2%) |
| Event | Fingolimod | Placebo |
|---|---|---|
| Herpes zosterInfections and infestations | 0/95 | 1/43 |
| Hip fractureInjury, poisoning and procedural complications | 0/95 | 1/43 |
| ParaparesisNervous system disorders | 1/95 | 0/43 |
| Event | Fingolimod | Placebo |
|---|---|---|
| HeadacheNervous system disorders | 18/95 | 4/43 |
| NasopharyngitisInfections and infestations | 15/95 | 8/43 |
| Upper respiratory tract infectionInfections and infestations | 11/95 | 6/43 |
| LymphopeniaBlood and lymphatic system disorders | 10/95 | 0/43 |
| NauseaGastrointestinal disorders | 2/95 | 4/43 |
| CoughRespiratory, thoracic and mediastinal disorders | 7/95 | 0/43 |
| DiarrhoeaGastrointestinal disorders | 3/95 | 3/43 |
| FatigueGeneral disorders | 3/95 | 3/43 |
| Urinary tract infectionInfections and infestations | 5/95 | 2/43 |
| Age Continuous(years) | Fingolimod | Placebo | Total |
|---|---|---|---|
| Mean | 37.4 ± 8.37 | 39.2 ± 8.67 | 37.9 ± 8.48 |
| Age, Customized(participants) | Fingolimod | Placebo | Total |
|---|---|---|---|
| 18-30 | 25 | 8 | 33 |
| 31-40 | 35 | 14 | 49 |
| 41-55 | 35 | 21 | 56 |
| Sex: Female, Male(Participants) | Fingolimod | Placebo | Total |
|---|---|---|---|
| Female | 65 | 29 | 94 |
| Male | 30 | 14 | 44 |
The record gives a start of Aug 2010, a primary completion of May 2011 and a completion of May 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2012, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fingolimod